Two former Alexion executives, both of whom resigned in the middle of a scandal two years ago, are starting a new biotech company — one with ambitious goals in cell and gene therapy, according to a new slide deck obtained by STAT.
The presentation provides some of the first details about the secretive new company, which its founders, including David Hallal and Vikas Sinha, are calling ElevateBio. They haven’t yet publicly discussed its existence or launched a website.
As the slide deck makes clear, ElevateBio already employs eight people, including Hallal and Sinha. It has plans to hire another 10 individuals and aims to move into a “base camp” facility at 790 Memorial Drive in Cambridge, Mass., by mid-January. According to job posting sites, many of those new hires will be focused on developing processes that use viruses to manipulate cells.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
